Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
1 "Soo Jung Hong"
Filter
Filter
Article category
Keywords
Publication year
Authors
Original Article
Weekly Gemcitabine and Docetaxel in Refractory Soft Tissue Sarcoma: A Retrospective Analysis
Ha-young Lee, Sang Joon Shin, Hyo Song Kim, Soo Jung Hong, Jung Woo Han, Seung Taek Lim, Jae Kyung Roh, Sun Young Rha
Cancer Res Treat. 2012;44(1):43-49.   Published online March 31, 2012
DOI: https://doi.org/10.4143/crt.2012.44.1.43
AbstractAbstract PDFPubReaderePub
PURPOSE
The combination of gemcitabine and docetaxel (GD) is used to effectively treat patients with soft tissue sarcoma (STS). It is widely considered that the conventional doses used are too high for long term use and many patients must discontinue GD treatment due to its toxicity. Therefore, to determine the appropriate dose meeting acceptable efficacy results, while minimizing toxic side effects, we treated patients with a weekly infusion of GD (weekly GD).
MATERIALS AND METHODS
A total of 22 patients presenting a variety of STSs were treated at Yonsei Cancer Center. All patients had metastatic or recurrent cancer and had previously received doxorubicin and ifosfamide combination chemotherapy. In all cases, gemcitabine (1,000 mg/m2) and docetaxel (35 mg/m2) were administered intravenously on days 1 and 8 of a 21-day cycle. We retrospectively reviewed the medical records of these patients.
RESULTS
The response rate was 4.5%, with one patient diagnosed with leiomyosarcoma having a partial response, and the disease control rate was 40.9%. The median progression-free survival (PFS) duration was 2.7 months and the PFS was correlated with the treatment response to a weekly GD. The median overall survival (OS) duration was 7.8 months and the OS was correlated with histology. There was no significant difference in OS between patients who received weekly GD as a 2nd line chemotherapy and those who received 3rd line or more. Treatment was generally well tolerated.
CONCLUSION
Weekly GD was well tolerated and showed moderate efficacy, indicating that this could be a reasonable option as a salvage treatment for metastatic STS.

Citations

Citations to this article as recorded by  
  • Comparative Evaluation of Second-Line Chemotherapy Agents for Advanced Soft Tissue Sarcoma: Gemcitabine/Docetaxel, Pazopanib, and Alternatives
    Tae Hun Kim, Ki Hyuk Sung, So Hak Chung
    Journal of the Korean Orthopaedic Association.2024; 59(1): 22.     CrossRef
  • 当科における再発・進行骨軟部肉腫に対するゲムシタビン+ドセタキセル療法の使用経験
    悠太 久保田, 正典 河野, 達也 岩﨑, 一朗 糸永, 信広 加来, 弘 津村, 和宏 田仲
    Orthopedics & Traumatology.2024; 73(2): 292.     CrossRef
  • Primary pleomorphic leiomyosarcoma of descending mesocolon
    Suhaildeen Kajamohideen, Balasubramanian Venkitaraman, Sathyanarayanan M Shivkumaran, Prithviraj Premkumar
    Formosan Journal of Surgery.2021; 54(5): 196.     CrossRef
  • Surgical resection of leiomyosarcoma of the inferior vena cava: A case series and literature review
    Maggie Zhou, Christopher Javadi, Greg W. Charville, Nam Q. Bui, E John Harris, George A. Poultsides, Jeffrey A. Norton, Brendan Visser, Byrne Lee, Monica M. Dua, Kristen N. Ganjoo
    Surgical Oncology.2021; 39: 101670.     CrossRef
  • Stabilization of Metastatic Uterine Leiomyosarcoma Using Pembrolizumab
    Katherine Cotangco, Mary Meram, M. Patrick Lowe
    Journal of the National Comprehensive Cancer Network.2020; 18(8): 1012.     CrossRef
  • Gemcitabine and docetaxel combination chemotherapy for advanced bone and soft tissue sarcomas: protocol for an open-label, non-randomised, Phase 2 study
    Hitomi Hara, Teruya Kawamoto, Naomasa Fukase, Yohei Kawakami, Toshiyuki Takemori, Shuichi Fujiwara, Kazumichi Kitayama, Kotaro Nishida, Ryosuke Kuroda, Toshihiro Akisue
    BMC Cancer.2019;[Epub]     CrossRef
  • Gemcitabine and Docetaxel Combination for Advanced Soft Tissue Sarcoma: A Nationwide Retrospective Study
    Yunjung Choi, Mi Sun Yun, Sang Hee Lim, Jeeyun Lee, Jin-Hee Ahn, Yu Jung Kim, Kyong Hwa Park, Young Suk Park, Ho Yeong Lim, Hyonggin An, Dong-Churl Suh, Yeul Hong Kim
    Cancer Research and Treatment.2018; 50(1): 175.     CrossRef
  • Establishment and characterization of a canine soft tissue sarcoma patient‐derived xenograft model
    J. P. Frazier, E. Beirne, S. H. Ditzler, I. Tretyak, J. R. Casalini, D. J. Thirstrup, S. Knoblaugh, J. G. Ward, C. D. Tripp, R. A. Klinghoffer
    Veterinary and Comparative Oncology.2017; 15(3): 754.     CrossRef
  • Feasibility and efficacy of gemcitabine and docetaxel combination chemotherapy for bone and soft tissue sarcomas: multi-institutional retrospective analysis of 134 patients
    Kazuhiro Tanaka, Susumu Joyama, Hirokazu Chuman, Hiroaki Hiraga, Hideo Morioka, Hideki Yoshikawa, Masami Hosaka, Mitsuru Takahashi, Tadahiko Kubo, Hiroshi Hatano, Mitsunori Kaya, Junya Toguchida, Yoshihiro Nishida, Akihito Nagano, Hiroshi Tsumura, Yukihid
    World Journal of Surgical Oncology.2016;[Epub]     CrossRef
  • A Phase II Study of Gemcitabine, Vincristine, and Cisplatin (Gvp) As Second-Line Treatment for Patients with Advanced Soft Tissue Sarcoma
    Zhiguo Luo, Xiaowei Zhang, Wei Peng, Xianghua Wu, Huijie Wang, Hui Yu, Jialei Wang, Jianhua Chang, Xiaonan Hong
    Medicine.2015; 94(43): e1777.     CrossRef
  • Emerging therapies for adult soft tissue sarcoma
    Stefano Radaelli, Sivia Stacchiotti, Paolo G Casali, Alessandro Gronchi
    Expert Review of Anticancer Therapy.2014; 14(6): 689.     CrossRef
  • A Randomized Phase II/III Trial of Perioperative Chemotherapy with Adriamycin Plus Ifosfamide Versus Gemcitabine Plus Docetaxel for High-grade Soft Tissue Sarcoma: Japan Clinical Oncology Group Study JCOG1306
    K. Kataoka, K. Tanaka, J. Mizusawa, A. Kimura, H. Hiraga, A. Kawai, T. Matsunobu, A. Matsumine, N. Araki, Y. Oda, H. Fukuda, Y. Iwamoto
    Japanese Journal of Clinical Oncology.2014; 44(8): 765.     CrossRef
  • Docetaxel-associated palmar-plantar erythrodysesthesia: A case report and review of the literature
    Christy S Harris, Dorothy Wang, Alison Carulli
    Journal of Oncology Pharmacy Practice.2014; 20(1): 73.     CrossRef
  • Gemcitabine and Docetaxel for Metastatic Soft Tissue Sarcoma - a Single Center Experience
    Thomas Schmitt, Florentina Kosely, Patrick Wuchter, Johann-Wilhelm Schmier, Anthony D. Ho, Gerlinde Egerer
    Oncology Research and Treatment.2013; 36(7-8): 415.     CrossRef
  • 12,240 View
  • 68 Download
  • 14 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP